The effect of chloroquine, hydroxychloroquine OR ivermectin in patients with severe manifestations of coronavirus

Phase 2

• Conditions: Coronavirus, non specifed location coronavirus infection; b34.2

• Registration Number: RBR-8h7q82
• Lead Sponsor: niversidade Federal de Roraima

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-02
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

laboratory test confirming infection by SARS-CoV-2 (positive serologic test IgM or rt-PCR); hospitalized with a clinical, epidemiological and radiological picture compatible with COVID-19; over 18 years old; present a severe form of the disease characterized by one of the following clinical signs: dyspnea, tachypnea (more than 30 irpm), peripheral oxygen saturation less than 93% (pulse oximeter evaluation), PaO2 / FiO2 ratio less than 300, or infiltrate pulmonary more than 50% of the parenchyma seen on chest tomography or chest radiography

Exclusion Criteria

under 18 years old; indigenous people; patients not fluent in Portuguese; unable to understand the objectives and methods of the study; critically ill patients who are not accompanied by legal representatives; those who reject participation in the study; patients with cardiac arrhythmia that include prolongation of the QT interval; previous use of any of the medications surveyed for more than 24 hours

Study & Design

• Study Type: Intervention
• Study Design: Not specified